Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab.

Journal of neuro-oncology - 9 Sept 2026

Loxterkamp Elizabeth, Luo Audrey, Sanvito Francesco, Le Collin T, Raymond Catalina, Yang Chuyin, Prins Terry J, Fisher Addison, Salamon Noriko, Liau Linda M, Chong Robert A, Nghiemphu Phioanh L, Nathanson David A, Cloughesy Timothy F, Lai Albert, Ellingson Benjamin M

Abstract excerpt

BACKGROUND: Pretreatment apparent diffusion coefficient (ADC) histogram analysis-specifically the lower Gaussian peak mean (ADC-L)-is a predictive biomarker of progression-free survival (PFS) and overall survival (OS) in recurrent IDH-wildtype glioblastoma receiving anti-VEGF treatment including bevacizumab. IDH-mutant gliomas differ biologically from glioblastoma, as they exhibit lower tumor cellularity, longer...

Read the complete abstract on PubMed

Topics

Humans
Bevacizumab
Brain Neoplasms
Female
Isocitrate Dehydrogenase

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Male

Retrospective Studies

Mutation

Neoplasm Recurrence, Local

Glioma

Diffusion Magnetic Resonance Imaging

Adult

Middle Aged

Antineoplastic Agents, Immunological

Progression-Free Survival

Prognosis

Aged

Follow-Up Studies

Source

Open in PubMed Open full text

Identifiers

PMID: 42717134
DOI: 10.1007/s11060-026-05782-2
PMCID: PMC13558324

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Diffusion histogram analysis predicts progression-free survival in contrast enhancing recurrent IDH mutant gliomas treated with bevacizumab.PMID 42717134Read ↗

Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden.Semantic proximity Read ↗

Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II TrialsSemantic proximity Read ↗

Validation of diffusion MRI phenotypes for predicting response to bevacizumab in recurrent glioblastoma: post-hoc analysis of the EORTC-26101 trial.Semantic proximity Read ↗

Predicting Genotype and Survival in Glioma Using Standard Clinical MR Imaging Apparent Diffusion Coefficient Images: A Pilot Study from The Cancer Genome Atlas.Semantic proximity Read ↗

Time-dependent diffusion MRI-based microstructural mapping for predicting IDH mutation status in glioma: A multicenter study.Semantic proximity Read ↗

Advanced imaging of IDH-mutant gliomas: Precision in diagnosis and management.Semantic proximity Read ↗

Perfusion, diffusion, and anatomical MRI characteristics of pathologically confirmed malignant transformation in IDH-mutant gliomas.Semantic proximity Read ↗

Association of dynamic susceptibility magnetic resonance imaging at initial tumor diagnosis with the prognosis of different molecular glioma subtypes.Semantic proximity Read ↗

Determinants of long-term survival in patients with IDH-mutant gliomas.Semantic proximity Read ↗

Radiological features combined with IDH1 status for predicting the survival outcome of glioblastoma patients.Semantic proximity Read ↗

Apparent Diffusion Coefficient as Imaging Biomarker for Identifying IDH Mutation, 1p19q Codeletion, and MGMT Promoter Methylation Status in Patients With Glioma.Semantic proximity Read ↗

Histopathological and molecular characteristics of IDH-wildtype glioblastoma without contrast enhancement: Implications for clinical outcomes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.